IPL 576092
Alternative Names: 4011; HMR 4011A; IPL 576,092Latest Information Update: 07 Feb 2017
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma; Atopic dermatitis; Ocular inflammation
Most Recent Events
- 07 Feb 2017 Discontinued - Phase-I for Asthma in Canada (Inhalation)
- 07 Feb 2017 Discontinued - Phase-I/II for Allergic rhinitis in Canada (Intranasal)
- 07 Feb 2017 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)